Core Viewpoint - The company expects significant revenue growth and a turnaround to profitability for the fiscal year ending December 31, 2025, driven by new product launches and effective cost control measures [1] Group 1: Revenue Expectations - The company anticipates revenue between approximately RMB 400 million and RMB 410 million for the fiscal year ending December 31, 2025, representing an increase of at least 43.9% compared to the revenue of RMB 278 million for the fiscal year ending December 31, 2024 [1] Group 2: Profitability Outlook - The company projects a pre-tax profit of approximately RMB 80 million for the fiscal year ending December 31, 2025, a significant improvement from a pre-tax net loss of RMB 12 million for the fiscal year ending December 31, 2024 [1] Group 3: Growth Drivers - Revenue growth is driven by several factors: 1. Launch of new products and technologies for ischemic stroke and an increase in market share for ischemic stroke products 2. Commercialization of intracranial stents and increased sales of other hemorrhagic stroke products 3. Continued growth in sales of interventional pathway products [1] - The company has effectively controlled costs through measures that reduced the expense ratio [1]
心玮医疗-B(06609.HK)：预计年度录得除税前利润约8000万元 同比转亏为盈